Qilu Pharma Spesolimab-sbzo Receives Suppl Approval in the U.S
Qilu Pharma Showcases QL1706 Clinical Trial Outcomes in Oral Presentation
Results from Trial of Qilu's Anticancer Agent QL1706 Featured in Presentation
Qilu`s Generic Lenalidomide Receives Approval in the U.S.
Results of Phase II Study on Qilu Pharmaceutical's Novel Drug QL1706 Published
Results of the Phase III Study on Qilu Pharmaceutical's Iruplinalkib Published
JINAN, China, Dec. 11, 2023 /PRNewswire/ -- During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster presentation (Poster No. 132P). The leading investigator of the study is Professor Lin Shen from the Peking University Cancer Hospital.
JINAN, China, Dec. 6, 2023 /PRNewswire/ -- Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster presentation at the European Society for Medical Oncology Asia Congress 2023 (ESMO Asia) taken place from December 1-3. Professor Weijian Guo from the Fudan University Shanghai Cancer Center and Professor Feng Bi from the West China Hospital, Sichuan University led the study.